Arthneeti

Godavari Drugs Share Price & Earnings Call Analysis

₹120.85-4.84% today
Market cap
₹132 Cr
P/E
33.90
ROE
6.14%
PEG
73.71
Price to sales
1.20
Debt to equity
1.08
52W high / low
₹140 / ₹70.2
Sales growth (5Y)
-2.91%
EBITDA margin
9.03%
Net profit margin
3.46%
Promoter holding
40.23%
Sales (last year)
₹110 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Godavari Drugs rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Godavari Drugs.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Godavari Drugs

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Godavari Drugs

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +37.3735.4239.5443.1138.6432.2126.0929.5525.5023.8126.6522.1833.16
Expenses +34.6933.1736.4739.5934.1728.9823.1926.9722.3920.9124.6519.7130.22
Operating Profit2.682.253.073.524.473.232.902.583.112.902.002.472.94
OPM %7.17%6.35%7.76%8.17%11.57%10.03%11.12%8.73%12.20%12.18%7.50%11.14%8.87%
Other Income +0.390.450.00-0.010.080.770.010.100.110.010.640.270.25
Interest1.031.111.301.271.231.441.081.111.111.000.911.110.96
Depreciation0.500.470.490.500.530.550.580.640.670.600.600.610.61
Profit before tax1.541.121.281.742.792.011.250.931.441.311.131.021.62
Tax %13.64%27.68%32.81%29.89%4.66%18.91%12.80%16.13%38.19%19.85%10.62%25.49%20.37%
Net Profit +1.330.810.861.222.661.631.090.770.891.041.000.761.29
EPS in Rs1.771.081.141.623.532.161.451.021.181.381.331.011.27

Financials of Godavari Drugs

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +557176648496123161160157113106
Expenses +49677060789011315015014310295
Operating Profit645456101110131210
OPM %11%6%7%6%7%6%8%7%6%8%10%10%
Other Income +001100001111
Interest123233334554
Depreciation111111122222
Profit before tax523122675765
Tax %23%38%33%37%31%13%28%25%23%20%22%19%
Net Profit +412112454644
EPS in Rs4.851.792.401.101.612.665.486.975.037.375.824.04
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Godavari Drugs

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8888888888810
Reserves679101113172226313666
Borrowings +81616192228302336586476
Other Liabilities +132124273336364952383548
Total Liabilities35515663748491101121135143200
Fixed Assets +7913151514222625273330
CWIP010129109183057
Investments000000000000
Other Assets +2741434757616875879081114
Total Assets35515663748491101121135143200

Financials of Godavari Drugs

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-6-55446111131811
Cash from Investing Activity +-0-2-3-3-2-7-1-5-9-13-20
Cash from Financing Activity +67-2-0-100-6-4-68
Net Cash Flow0001-0-0011-0-0
Free Cash Flow-6-7101-1-0645-9
CFO/OP-101%-101%108%109%73%108%26%110%143%146%105%

Financials of Godavari Drugs

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days87126117152148137134126132138136150
Inventory Days846770100938455285762125217
Days Payable7910812417117114411212113296128163
Cash Conversion Cycle928563817078783358105133204
Working Capital Days63444047383146322391142
ROCE %32%16%17%11%12%12%18%18%14%14%10%7%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals